Drug Approval | November 22, 2023
Truqap plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The companies plan to start a pivotal Phase 3 trial in the coming months
The company expects that this development could improve the strength of its application to the FDA for new drug approval
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
